Patent ID: 11905522
Assignee: CLS THERAPEUTICS, LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 0:
1. A method for inhibiting growth of a primary tumor in a subject having a cancer accompanied by accumulation of cell free DNA (cfDNA) in the hepatic porto-sinusoidal circulation of the subject, said method comprising administering to the subject a therapeutically effective amount of a recombinant adeno-associated virus (rAAV) expression vector comprising (i) a capsid protein and (ii) a nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding an enzyme which has a deoxyribonuclease (DNase) activity, wherein the promoter is a liver-specific promoter, wherein the nucleic acid comprises the sequence of SEQ ID NO: 30 or SEQ ID NO: 31, and wherein the administration of the rAAV vector results in inhibiting growth of the primary tumor in the subject.